Intermittent Fasting and Exercise Show Added Weight-Loss Benefits in Adults With Obesity
Intermittent fasting plus exercise may boost short-term weight loss in adults with obesity, but liver fat benefits were not greater than standard care.
News on obesity, weight management and weight-loss medicines such as GLP-1 drugs.
NICE Updates Pregnancy Nutrition Guidance as UK Focus Shifts to Maternal Weight Management
NICE has updated guidance on pregnancy nutrition and child feeding, sharpening UK focus on maternal weight management and early-life health.
Personalized Nutrition Shows Promise for Weight Loss in New Study
New study suggests personalized nutrition may help people lose weight more effectively than calorie counting or restrictive diets.
Higher Liver Fat Reduction Seen With Ketogenic Diet in New Weight-Loss Trial
A new trial found ketogenic diets reduced liver fat more than Mediterranean or plant-forward plans after similar weight loss.
GLP-1 Drugs Could Reshape Obesity Care, but UK Clinicians Still Have Questions
UK clinicians see promise in GLP-1 obesity drugs, but questions remain about training, behavioural care and long-term use.
Weight Loss Drugs May Ease Binge Eating Symptoms, BMJ Reports
BMJ reports that weight loss drugs could reduce binge eating disorder symptoms, adding to growing interest in GLP-1 medicines.
Eight-Hour Eating Window May Help Sustain Weight Loss, Study Suggests
A new study suggests an eight-hour eating window may help overweight adults sustain weight loss for 12 months.
UK Obesity Debate Intensifies as New Evidence Points to Rising Risks in Younger Adults
New BMJ evidence shows obesity rising fastest in young adults in England, intensifying calls for broader UK nutrition action.
Diet Coaching Helps Weight Loss Regardless of Genetic Obesity Risk, Study Finds
A study suggests dietary coaching aids weight loss equally, regardless of genetic obesity risk, challenging genetic determinism.
UK Doctors May Soon Reconsider Wegovy’s New Oral Form as Demand for Weight-Loss Treatment Grows
UK doctors face new questions as oral semaglutide is authorised for obesity, with diet and activity still central to care.
